Marginal zone lymphomas (MZL) are collectively the second most common indolent
lymphoma comprising 7% of all non-Hodgkin lymphomas with 7,460 patients diagnosed in …

In the last update of the World Health Organization (WHO) classification, the marginal zone
B-cell lymphomas (MZLs) comprise extranodal MZL (EMZL) of mucosa-associated lymphoid …

Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a
heterogeneous group of malignancies sharing similar disease courses and treatment …

Disease overview Marginal zone lymphomas (MZL) are collectively the second most
common type of indolent lymphoma. Diagnosis Three subtypes of MZL are recognized …

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes
durable disease control in patients with splenic marginal zone lymphoma (SMZL). However …

Although classical Hodgkin lymphoma (cHL) is usually curable, 20–30% of the patients
experience treatment failure and most of them are typically treated with salvage …

Objectives: To examine the use of splenectomy, chemotherapy, and subsequent overall
survival (OS) in contemporary patients with splenic lymphomas. Methods: We analyzed …

Marginal zone lymphomas (MZLs) represent about 7% of B-cell non-Hodgkin lymphomas
and include 3 different subtypes—namely, extranodal (EMZL), nodal, and splenic (SMZL) …

The aim of this study was to explore the efficacy and safety of obinutuzumab (G)-versus
rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal …

The spleen, body's largest secondary lymphoid organ, is also a vital hematopoietic and
immunological organ. It is regarded as one of the most significant organs in humans. As …